CT-2106 for the Second Line Treatment of Ovarian Cancer

Inclusion Criteria: * Patients with advanced ovarian carcinoma, who have failed one prior platinum and taxane containing regimen * Only one prior chemotherapy containing either cisplatin or carboplatin plus taxanes administered concomitantly * At least one measurable lesion according to RECIST * ECOG performance status 0 or 1 * at least 18 years old * Adequate haematological function * Adequate renal and hepatic functions * Normal coagulation parameters Exclusion Criteria: * Platinum-sensitive patients (Group 2) who responded (CR or PR) to a 1st line therapy and subsequently progressed or relapsed after a treatment-free interval of \> 12 months * Pregnant or lactating patients * Prior treatment with camptothecins * Presence or history of CNS metastasis or carcinomatous leptomeningitis; * Current active infection per investigator assessment; * Unresolved bowel obstruction or subobstruction, uncontrolled Crohn's disease or ulcerative colitis; * Current history of chronic diarrhea \>= grade 1 (CTCAE version 3); * Surgery or radiotherapy ≤ 4 weeks before first study treatment. In case of cytoreductive surgery for the progression of the disease, ≤ 2 weeks before the 1st study treatment are allowed; * Other uncontrolled, serious illness or medical condition, as determined by the investigator; * Concomitant (or within 4 weeks before inclusion) administration of any other experimental drug under investigation; * Concurrent treatment with any other anti-cancer therapy; * Known HIV positivity or AIDS-related illness; * Patients who cannot be regularly followed up for psychological, social, familial or geographic reasons.